Medpace, Inc. recently announced the opening of additional Medpace offices in Scotland and Italy, bringing the total number of Medpace offices to ten across Europe. In addition, Medpace has appointed additional leadership for these countries and offices.
The Medpace Scotland office is led by Ellie Robertson, providing safety services for clinical operations in Europe as well as clinical trial management, clinical monitoring, and clinical regulatory submission services. The Medpace Milan office, led by Vincenzo Lopreiato, Country Manager, will facilitate and support the conduct of clinical studies in this important country.
Rounding out the European group, Medpace welcomes Helena Lüning as a Country Manager for Sweden where she will lead the clinical operations team in Stockholm.
The addition of these clinical experts and new offices will support an expansive Medpace European group, led by Dr. Dieter Seitz-Tutter, Vice President, Europe, in the delivery of therapeutic study direction, full-service monitoring, and trial management services in tandem with existing European offices. Continuing to invest in organic growth in Europe supports Medpace's ability to deliver seamless integration and quality global operation procedures for sponsors.
"Medpace is a global organization known for full-service, therapeutically-driven operations in the United States, however, with a quickly expanding European group of clinical expertise and infrastructure, Medpace will be able to replicate excellence in service for global studies,? said Dr. Seitz-Tutter, Vice President, Europe. ?Medpace continues to grow to support clinical studies conducted in Europe, and investment for these initiatives is an ongoing process."
Medpace, a US-based, midsized, therapeutically specialized clinical research organization, has expanded in both emerging markets and Europe, particularly in oncology, cardiovascular, and metabolic studies. The addition of this country specific leadership enables Medpace to support its European sponsors and facilitate growth on a global platform.
Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services.
Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.
With more than 1000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from imaging services (Imagepace), and medical device development from Medpace Medical Device. For more information, visit www.medpace.com.
SOURCE: Medpace, Inc.